Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

Novo Nordisk logo

Novo Nordisk

Status and phase

Completed
Phase 2

Conditions

Diabetes
Diabetes Mellitus, Type 2

Treatments

Drug: liraglutide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00154414
NN2211-1334
JapicCTI-050131 (Registry Identifier)

Details and patient eligibility

About

This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.

Enrollment

226 patients

Sex

All

Ages

20 to 74 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects diagnosed with type 2 diabetes and treated with diet therapy with or without single oral drug therapy
  • 7.0 % =< HbA1c < 10.0 %
  • Body Mass Index (BMI) < 30.0 kg/m^2

Exclusion criteria

  • Subjects treated with thiazolidinediones or insulin
  • Subjects with any serious medical conditions

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems